Lexaria raises $5.9M by repricing warrants to extend runway into 2027
What's the deal? Lexaria BioscienceDealroom has a profile for this one. Try Dealroom → (NASDAQ: LEXX) has entered into agreements for the immediate exercise of outstanding warrants, raising roughly $5.9 million in gross proceeds before fees. H.C. WainwrightDealroom has a profile for this one. Try Dealroom → & Co. is acting as exclusive placement agent.
The mechanics: The company will issue 453,969 shares upon exercise of warrants originally issued between February 2024 and December 2025. To incentivise the exercise, Lexaria cut the price from an original range of $17.85 to $45.90 per share down to $12.92. The transaction is expected to close on or about September 9, 2026.
What else? Lexaria will issue new unregistered Series A and Series B warrants to buy up to 453,969 more shares at $12.67 each. The Series A warrants expire five years from the effective date of a resale registration statement; the Series B warrants expire 18 months after.
What's the money for? Net proceeds are earmarked for working capital and general corporate purposes. Management said the funds, combined with a $2.6 million tax rebate recently received from the Australian Tax Office, may fund operations and R&D programs in 2027.
What could go wrong? The deal avoids a new offering at current prices, but the exercise and new warrants add potential dilution. The immediate 453,969-share issuance lifts the count, with further dilution possible as the fresh warrants are exercised.
The signal: Repricing warrants to pull forward cash is a familiar move for small-cap biotechs seeking runway without a fresh raise. For Lexaria, it buys time to push its R&D programs into 2027 while sidestepping a discounted equity round at today's market price.
Read more: minichart.com.sg
Image credit: foteih
